pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,530 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1829Endpoints1417Fierce Biotech738BioSpace726BioPharma Dive538raps241onclive165fda recalls
therapy area
allOncology12566Rare Disease3282Immunology2963Cardiology2832Hematology2224Pulmonology2202Vaccines
  • CG Oncology's oncolytic therapy shows positive Phase 3 results in non-muscle invasive bladder cancer
    CG Oncology announced that its oncolytic immunotherapy, cretostimogene grenadenorepvec, achieved its primary endpoints in a Phase 3 trial involving patients with non-muscle invasive bladder cancer.…
    Endpoints · 1h agoPositive readoutPositive↗ source
  • Versant and Eli Lilly commit $100 million to launch Seawolf Therapeutics, a non-viral gene-therapy startup
    Versant Ventures, Eli Lilly and other investors announced a $100 million financing round to create Seawolf Therapeutics, a new company focused on non-viral gene delivery. The startup aims to overc…
    STAT · 4h agoDealPositive↗ source
← prev
page 1 of 62
next →
116
fda medwatch112
globenewswire health73
fda press59
1821
Psychiatry & CNS1224
Ophthalmology1087
Endocrinology & Metabolism792
Pain784
Nephrology767
  • Biopharma firms showcase non-amyloid Alzheimer’s strategies at CTAD 2026 conference
    Biopharma companies including Biogen, Bristol Myers Squibb and Roche gathered in Boston for the Clinical Trials on Alzheimer’s Disease (CTAD) 2026 conference, where they presented new data on their…
    BioSpace · 9h agoPositive↗ source
  • Novartis and BMS pause autoimmune CAR-T trials after patient deaths and safety concerns
    Novartis, Bristol Myers Squibb and several other biotech firms have recently encountered setbacks while developing therapies for autoimmune diseases. Some programs have been completely discontinued…
    BioSpace · 9h agoNegative readoutNegative↗ source
  • BeOne Medicines and Hengrui Lead STAT-WireScreen’s China Biotech Powerhouse 25 Ranking
    STAT and risk‑intelligence platform WireScreen have published a new ranking called China’s Biotech Powerhouse 25, which lists the most valuable publicly traded biotech companies in the country. Th…
    STAT · 4h agoNeutral↗ source
  • BridgeBio's Morgan Paull and Christine Zhang Named BioSpace 40 Under 40, Emphasize Patient-Centric Model
    BridgeBio has seen two of its young executives, Morgan Paull and Christine Zhang, named to BioSpace’s 2026 40 Under 40 list. Their inclusion highlights the company’s rapid growth and focus on rare-…
    BioSpace · 8h agoPositive↗ source
  • Apple and OpenEvidence Begin Study of Experimental AI Health Chat App
    Apple and OpenEvidence have launched a study centered on an experimental AI-powered health chat application. The pilot allows users to link personal health data to the chatbot, which then provides…
    STAT · 12h agoNeutral↗ source
  • CLINUVEL to cut up to 20% of staff and move headquarters to New York
    CLINUVEL announced a strategic reorganization aimed at focusing resources on the U.S. market. The company will reduce its global workforce by 10% to 20%, affecting up to 21 of its 104 employees.…
    BioSpace · 12h agoLayoffsNegative↗ source
  • FDA denies Summit Therapeutics' ivonescimab for EGFR-mutated lung cancer, halting US entry
    The U.S. Food and Drug Administration issued a complete response letter rejecting Summit Therapeutics' biologics license application for ivonescimab, a PD-1xVEGF bispecific antibody intended for EG…
    BioSpace · 1d agoCRLNegative↗ source
  • FDA rejects Summit and Akeso's ivonescimab for narrow lung cancer
    The U.S. Food and Drug Administration has turned down ivonescimab, a new cancer therapy being developed by Summit Therapeutics and Akeso, for use in a specific type of lung cancer. Analysts had la…
    Endpoints · 1d agoRegulatoryNegative↗ source
  • STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics
    The FDA has rejected ivonescimab, a treatment for a type of lung cancer developed by U.S. biotech Summit Therapeutics and the Chinese drugmaker Akeso.
    STAT · 23h ago↗ source
  • Moderna says it is ready to produce thousands of doses of its Merck-partnered cancer vaccine ahead of FDA filing
    Moderna announced that it is on track to manufacture large quantities of a cancer vaccine developed in partnership with Merck. The company says production facilities are prepared to produce thousa…
    Endpoints · 2d agoRegulatoryPositive↗ source
  • FDA issues complete response letter, rejecting Summit Therapeutics' ivonescimab for EGFR-mutated lung cancer
    The U.S. Food and Drug Administration sent a complete response letter to Summit Therapeutics, declining to approve its bispecific antibody ivonescimab for patients with previously treated EGFR‑muta…
    Fierce Biotech · 2d agoRegulatoryNegative↗ source
  • Arrowhead faces challenges as Ionis's Tryngolza sales fall short, putting sHTG launch at risk
    Ionis Pharmaceuticals reported flat sales of its severe hypertriglyceridemia drug Tryngolza, generating only $9 million and cutting its annual revenue outlook to $50 million. The weak performance…
    BioSpace · 2d agoEarningsNegative↗ source
  • Setbacks in two heart disease trials raise questions about future cardiovascular drug research
    A recent episode of The Readout LOUD highlighted the disappointing results of two high-profile heart disease drugs, noting that both failed to demonstrate benefit in recent studies. The failures w…
    STAT · 3d agoNegative readoutNegative↗ source
  • Rezolute’s phase 3 trial of ersodetug meets primary endpoint in tumor hyperinsulinism
    Rezolute reported that its phase 3 Uplift study of ersodetug in tumor hyperinsulinism achieved its primary endpoint. The trial required at least nine of 16 patients to show a 50% or greater reduct…
    Fierce Biotech · 3d agoPositive readoutPositive↗ source
  • Virtuoso Surgical receives FDA De Novo clearance for robotic bladder lesion removal system
    Virtuoso Surgical's Virtuoso Endoscopy System received FDA De Novo authorization, marking the first device in a new classification for electromechanical surgical technologies that use robotic instr…
    Fierce Biotech · 3d agoApprovalPositive↗ source
  • Synchron pauses second-generation brain-computer interface trial, says pause not safety related
    Synchron, a brain-implant startup, announced it is pausing enrollment in its second-generation brain-computer interface trial. Company officials emphasized the decision is operational and not driv…
    STAT · 2d agoNeutral↗ source
  • Gubra appoints ex-HHS official Brett Giroir as co-CEO after sudden exit of Markus Rohrwild
    Gubra, the Danish obesity partner of AbbVie and Boehringer Ingelheim, announced a leadership change following the abrupt departure of its CEO, Markus Rohrwild. The company will operate under a co…
    Endpoints · 3d agoNeutral↗ source
  • American Cancer Society updates prostate cancer screening guidance
    For the first time in 16 years, the American Cancer Society (ACS) has updated its guideline for prostate cancer screening as it drives to boost detection of the disease before it spreads.
    Fierce Biotech · 3d ago↗ source
  • Sofinnova Partners closes €725 million (≈$815 million) Crossover II fund to back ~15 European clinical-stage biotech firms
    Sofinnova Partners announced the closing of its largest fund to date, Crossover II, with €725 million (about $815 million) in capital. The fund plans to invest in roughly 15 clinical‑stage compani…
    Fierce Biotech · 3d agoDealPositive↗ source
  • Scientists release detailed basal ganglia cell map, uncover new neuron linked to schizophrenia
    Scientists from a large international collaboration have created the most detailed map of the basal ganglia, a brain region that coordinates movement and emotion. The effort profiled over 25 millio…
    STAT · 3d agoPositive↗ source
  • Bristol Myers Squibb reshuffles R&D leadership as chief research officer departs and CMO takes over combined unit
    Bristol Myers Squibb announced a restructuring of its research and development organization, merging the separate research and development divisions into a single unit. The new combined R&D unit w…
    Fierce Biotech · 3d agoNeutral↗ source
  • EnGene reports improved bladder cancer data after May setback
    EnGene, a biotech developing a bladder cancer therapy, released new data that appear more encouraging than the results disclosed in May. The May data had shown limited durability, causing a sharp…
    Endpoints · 3d agoPositive readoutPositive↗ source
  • Parker Institute chief urges renewed focus on cancer immunotherapy after mixed results from Revolution Medicines' drug
    Ira Mellman, who leads research at the Parker Institute for Cancer Immunotherapy, said on Sept. 16, 2026 that he felt disappointment and frustration as the industry celebrated Revolution Medicines'…
    Endpoints · 4d agoNegative↗ source